{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T04:06:26Z","timestamp":1779854786652,"version":"3.53.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Geriatr"],"DOI":"10.1186\/s12877-025-06912-7","type":"journal-article","created":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T11:52:21Z","timestamp":1767095541000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Grade 4 thrombocytopenia with PD-1 inhibitors following progression of PD-L1 inhibitor therapy in small cell lung cancer: a case report and literature review"],"prefix":"10.1186","volume":"26","author":[{"given":"An","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongxiao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yibing","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuhui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,30]]},"reference":[{"issue":"3","key":"6912_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"6912_CR2","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.trecan.2024.07.008","volume":"10","author":"E Redin","year":"2024","unstructured":"Redin E, Quintanal-Villalonga \u00c1, Rudin CM. Small cell lung cancer profiling: an updated synthesis of subtypes, vulnerabilities, and plasticity. Trends Cancer. 2024;10(10):935\u201346. https:\/\/doi.org\/10.1016\/j.trecan.2024.07.008.","journal-title":"Trends Cancer"},{"issue":"5","key":"6912_CR3","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1634\/theoncologist.2018-0574","volume":"24","author":"EJ Davis","year":"2019","unstructured":"Davis EJ, Salem JE, Young A, et al. Hematologic complications of immune checkpoint inhibitors. Oncologist. 2019;24(5):584\u20138. https:\/\/doi.org\/10.1634\/theoncologist.2018-0574.","journal-title":"Oncologist"},{"issue":"10212","key":"6912_CR4","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","volume":"394","author":"L Paz-Ares","year":"2019","unstructured":"Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet (lond Engl). 2019;394(10212):1929\u201339. https:\/\/doi.org\/10.1016\/S0140-6736(19)32222-6.","journal-title":"Lancet (lond Engl)"},{"issue":"9","key":"6912_CR5","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1038\/s41591-023-02498-y","volume":"29","author":"A VanderWalde","year":"2023","unstructured":"VanderWalde A, Bellasea SL, Kendra KL, et al. Ipilimumab with or without nivolumab in PD-1 or PD-L1 Blockade refractory metastatic melanoma: a randomized phase 2 trial. Nat Med. 2023;29(9):2278\u201385. https:\/\/doi.org\/10.1038\/s41591-023-02498-y.","journal-title":"Nat Med"},{"issue":"24","key":"6912_CR6","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.1200\/JCO.21.00079","volume":"39","author":"DJ Olson","year":"2021","unstructured":"Olson DJ, Eroglu Z, Brockstein B, et al. Pembrolizumab plus ipilimumab following anti-PD-1\/L1 failure in melanoma. J Clin Oncol: Off J Am Soc Clin Oncol. 2021;39(24):2647\u201355. https:\/\/doi.org\/10.1200\/JCO.21.00079.","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"9","key":"6912_CR7","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1016\/j.ccell.2023.08.004","volume":"41","author":"BG Topp","year":"2023","unstructured":"Topp BG, Channavazzala M, Mayawala K, et al. Tumor dynamics in patients with solid tumors treated with pembrolizumab beyond disease progression. Cancer Cell. 2023;41(9):1680\u2013e16882. https:\/\/doi.org\/10.1016\/j.ccell.2023.08.004.","journal-title":"Cancer Cell"},{"issue":"8","key":"6912_CR8","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1007\/s11886-021-01530-2","volume":"23","author":"DJ Lee","year":"2021","unstructured":"Lee DJ, Lee HJ, Farmer JR, Reynolds KL. Mechanisms driving immune-related adverse events in cancer patients treated with immune checkpoint inhibitors. Curr Cardiol Rep. 2021;23(8):98. https:\/\/doi.org\/10.1007\/s11886-021-01530-2.","journal-title":"Curr Cardiol Rep"},{"issue":"18","key":"6912_CR9","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1200\/JCO.2014.60.0379","volume":"33","author":"JS Weber","year":"2015","unstructured":"Weber JS, Yang JC, Atkins MB, Disis ML. Toxicities of immunotherapy for the practitioner. J Clin Oncol: Off J Am Soc Clin Oncol. 2015;33(18):2092\u20139. https:\/\/doi.org\/10.1200\/JCO.2014.60.0379.","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"10027","key":"6912_CR10","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet (lond Engl). 2016;387(10027):1540\u201350. https:\/\/doi.org\/10.1016\/S0140-6736(15)01281-7.","journal-title":"Lancet (lond Engl)"},{"key":"6912_CR11","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40425-017-0210-0","volume":"5","author":"E Shiuan","year":"2017","unstructured":"Shiuan E, Beckermann KE, Ozgun A, et al. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy. J ImmunoTher Cancer. 2017;5:8. https:\/\/doi.org\/10.1186\/s40425-017-0210-0.","journal-title":"J ImmunoTher Cancer"},{"issue":"1","key":"6912_CR12","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1016\/S2352-3026(18)30175-3","volume":"6","author":"N Delanoy","year":"2019","unstructured":"Delanoy N, Michot JM, Comont T, et al. Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study. Lancet Haematol. 2019;6(1):e48\u201357. https:\/\/doi.org\/10.1016\/S2352-3026(18)30175-3.","journal-title":"Lancet Haematol"},{"key":"6912_CR13","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ejca.2019.07.014","volume":"122","author":"JM Michot","year":"2019","unstructured":"Michot JM, Lazarovici J, Tieu A, et al. Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage? Eur J Cancer (oxf Engl: 1990). 2019;122:72\u201390. https:\/\/doi.org\/10.1016\/j.ejca.2019.07.014.","journal-title":"Eur J Cancer (oxf Engl: 1990)"},{"issue":"4","key":"6912_CR14","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.3390\/ijms25042163","volume":"25","author":"A Mititelu","year":"2024","unstructured":"Mititelu A, Onis\u00e2i MC, Ro\u0219ca A, Vl\u0103d\u0103reanu AM. Current Understanding of immune thrombocytopenia: A review of pathogenesis and treatment options. Int J Mol Sci. 2024;25(4):2163. https:\/\/doi.org\/10.3390\/ijms25042163.","journal-title":"Int J Mol Sci"},{"key":"6912_CR15","doi-asserted-by":"publisher","first-page":"102556","DOI":"10.1016\/j.coi.2025.102556","volume":"94","author":"Y Sun","year":"2025","unstructured":"Sun Y, Zhang Z, Jia K, Liu H, Zhang F. Autoimmune-related adverse events induced by immune checkpoint inhibitors. Curr Opin Immunol. 2025;94:102556. https:\/\/doi.org\/10.1016\/j.coi.2025.102556.","journal-title":"Curr Opin Immunol"},{"key":"6912_CR16","doi-asserted-by":"publisher","first-page":"790051","DOI":"10.3389\/fimmu.2021.790051","volume":"12","author":"W Xie","year":"2021","unstructured":"Xie W, Hu N, Cao L. Immune thrombocytopenia induced by immune checkpoint inhibitrs in lung cancer: case report and literature review. Front Immunol. 2021;12:790051. https:\/\/doi.org\/10.3389\/fimmu.2021.790051.","journal-title":"Front Immunol"},{"issue":"4","key":"6912_CR17","doi-asserted-by":"publisher","first-page":"580","DOI":"10.3390\/cancers11040580","volume":"11","author":"SY Liu","year":"2019","unstructured":"Liu SY, Huang WC, Yeh HI, et al. Sequential Blockade of PD-1 and PD-L1 causes fulminant cardiotoxicity-from case report to mouse model validation. Cancers. 2019;11(4):580. https:\/\/doi.org\/10.3390\/cancers11040580.","journal-title":"Cancers"},{"key":"6912_CR18","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.3389\/fonc.2019.01437","volume":"9","author":"X Liang","year":"2019","unstructured":"Liang X, Guan Y, Zhang B, et al. Severe immune-related pneumonitis with PD-1 inhibitor after progression on previous PD-L1 inhibitor in small cell lung cancer: a case report and review of the literature. Front Oncol. 2019;9:1437. https:\/\/doi.org\/10.3389\/fonc.2019.01437.","journal-title":"Front Oncol"},{"issue":"12","key":"6912_CR19","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","volume":"33","author":"J Haanen","year":"2022","unstructured":"Haanen J, Obeid M, Spain L, et al. Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol: Off J Eur Soc Med Oncol. 2022;33(12):1217\u201338. https:\/\/doi.org\/10.1016\/j.annonc.2022.10.001.","journal-title":"Ann Oncol: Off J Eur Soc Med Oncol"},{"issue":"36","key":"6912_CR20","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol: Off J Am Soc Clin Oncol. 2021;39(36):4073\u2013126. https:\/\/doi.org\/10.1200\/JCO.21.01440.","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"6","key":"6912_CR21","doi-asserted-by":"publisher","first-page":"e002435","DOI":"10.1136\/jitc-2021-002435","volume":"9","author":"JR Brahmer","year":"2021","unstructured":"Brahmer JR, Abu-Sbeih H, Ascierto PA, et al. Society for immunotherapy of cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J ImmunoTher Cancer. 2021;9(6):e002435. https:\/\/doi.org\/10.1136\/jitc-2021-002435.","journal-title":"J ImmunoTher Cancer"},{"issue":"7","key":"6912_CR22","doi-asserted-by":"publisher","first-page":"535","DOI":"10.3760\/cma.j.issn.0253-2727.2023.07.002","volume":"44","author":"Thrombosis and Hemostasis Group, Chinese Society of Hematology, Chinese Medical Association","year":"2023","unstructured":"Thrombosis and Hemostasis Group, Chinese Society of Hematology, Chinese Medical Association. [chinese expert consensus on the clinical application of Recombinant human thrombopoiein and thrombopoiein receptor agonist (2023)]. Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi. 2023;44(7):535\u201342. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-2727.2023.07.002.","journal-title":"Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi"},{"issue":"33","key":"6912_CR23","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.3760\/cma.j.cn112137-20230409-00575","volume":"103","author":"Society of Chemotherapy, China Anti-Cancer Association, Committee of Neoplastic Supportive-Care, China Anti-Cancer Association","year":"2023","unstructured":"Society of Chemotherapy, China Anti-Cancer Association, Committee of Neoplastic Supportive-Care, China Anti-Cancer Association. [consensus on the clinical diagnosis, treatment and prevention of cancer treatment-induced thrombocytopenia in China (2023 edition)]. Zhonghua Yi Xue Za Zhi. 2023;103(33):2579\u201390. https:\/\/doi.org\/10.3760\/cma.j.cn112137-20230409-00575.","journal-title":"Zhonghua Yi Xue Za Zhi"}],"container-title":["BMC Geriatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12877-025-06912-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12877-025-06912-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12877-025-06912-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T03:44:58Z","timestamp":1779853498000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12877-025-06912-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,30]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6912"],"URL":"https:\/\/doi.org\/10.1186\/s12877-025-06912-7","relation":{},"ISSN":["1471-2318"],"issn-type":[{"value":"1471-2318","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,30]]},"assertion":[{"value":"6 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: authors An Wang, Yi Dong, and Dongxiao Wu are recognized as equal contributors.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This case report was approved by the ethics committee of the Chinese PLA General Hospital (No. S2023-409-01). We certify that the study was performed in accordance with the 1964 Declaration of HELSINKI and later amendments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Consent for publication"}},{"value":"The authors report there are no competing interests to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Competing interests"}}],"article-number":"167"}}